Alloplex Biotherapeutics has developed a novel cellular therapy platform known as SUPLEXA, which is designed to treat various types of cancer through a non-engineered approach. This platform utilizes specially engineered tumor cell lines, referred to as ENLIST cells, which express multiple immunomodulatory ligands. These ligands activate and differentiate human peripheral blood mononuclear cells (PBMCs) to generate anti-tumor cells. The SUPLEXA therapeutic cells that emerge from this process exhibit broad anti-tumor activity and are characterized by a heightened state of activation, enabling them to effectively recognize and kill tumor cells while sparing normal immune cells. This unique mechanism of action is based on the simultaneous activation of multiple immune pathways, which has shown to produce a synergistic effect that enhances the overall anti-tumor response.

The manufacturing process for SUPLEXA therapeutic cells is designed to be simple, reproducible, and GMP-compliant, allowing for consistent high yields without the need for genetic engineering. This approach mitigates many of the challenges associated with traditional autologous therapies, such as variability in cellular composition and potential safety risks. Early results from ongoing Phase 1 clinical trials indicate that SUPLEXA therapeutic cells have a favorable safety profile and demonstrate promising clinical activity against solid tumors. The innovative design of this therapy, which leverages the natural immune response without genetic modification, positions Alloplex as a pioneer in the field of cancer immunotherapy, with the potential for future developments in allogeneic applications.

United States

Alloplex Biotherapeutics is dedicated to exploring the higher order combinatorial space of immunomodulators to develop an effective anti-tumor vaccine. This approach is applicable to all tumor types and is particularly suited to combinations with checkpoint inhibitors. Alloplex is a private company and currently supported by angel investment

Alloplex Biotherapeutics

Company Details